Daily urinary neopterin excretion as an immunological marker of disease activity in multiple sclerosis.

The aim of this study was to assess neopterin, a marker of interferon gamma (IFN-gamma) induced macrophage activity, as a possible surrogate marker of inflammation in patients with multiple sclerosis. Urinary neopterin to creatinine ratios (UNCRs) were measured daily in 10 primary progressive (PP). 10 relapsing remitting (RR) and 11 secondary progressive (SP) patients with multiple sclerosis, and 14 normal control (NC) subjects, for periods of up to 12 weeks. After excluding measurements related to infection, the median of the individuals' average UNCRs was significantly higher in patients than in controls (P < 0.001 for all patients and P < 0.01 for each of the three groups of patients); the median UNCRs (and interquartile ranges) were 187 (135-231), 187 (165-277), 218 (164-517) and 134 (97-152) mumol/mol for PP, RR, SP patients and controls, respectively. Similarly, patients had a greater median proportion of days with a UNCR above normal (P < 0.001 for all patients and P < 0.01 for each group); the median percentage (and interquartile ranges) were 16 (6-62), 28 (21-36), 49 (14-86) and 0 (0-6)% for PP, RR, SP patients and controls, respectively. They also had a greater number of peaks in their serial UNCR measurements than controls (P < 0.001 for all patients and P < 0.01 for each group); the means +/- SD peaks/subject/month were: 2.1 +/- 1.8; 3.0 +/- 1.7; 3.3 +/- 2.3 and 0.2 +/- 0.6 for PP, RR, SP patients and controls, respectively. Nine relapses occurred in nine patients during the study, and all were associated with increased neopterin excretion, which tended to be greater than that on days not associated with a relapse. Three of the nine relapses were preceded by an upper respiratory tract infection. In eight out of 13 patients who had infections during the study, increased neopterin excretion was noted for periods of up to 6 weeks post-infection, significantly longer than that which occurred after infections in controls. This confirms infection as a potent inducer of symptomatic and asymptomatic disease activity in mutiple sclerosis, and provides further support of a pivotal role for IFN-gamma in te pathogenesis of mutiple sclerosis. Urinary neopterin excretion is increased in patients with both progressive and relapsing mutiple sclerosis, and therefore has potential as a surrogate marker of the inflammatory component of mutiple sclerosis disease activity.

[1]  H. Panitch.  Influence of infection on exacerbations of multiple sclerosis , 2004, Annals of neurology.

[2]  G. Barker,et al.  MRI dynamics of brain and spinal cord in progressive multiple sclerosis. , 1996, Journal of neurology, neurosurgery, and psychiatry.

[3]  C. Raine,et al.  The adhesion molecule and cytokine profile of multiple sclerosis lesions , 1995, Annals of neurology.

[4]  P. Matthews,et al.  Use of proton magnetic resonance spectroscopy for monitoring disease progression in multiple sclerosis , 1994, Annals of neurology.

[5]  A. Alpérovitch,et al.  Validation of self-reported neurological disability in multiple sclerosis. , 1994, International Journal of Epidemiology.

[6]  A. Thompson,et al.  Major differences in the dynamics of primary and secondary progressive multiple sclerosis , 1991, Annals of neurology.

[7]  E. Werner,et al.  Neopterin formation and tryptophan degradation by a human myelomonocytic cell line (THP-1) upon cytokine treatment. , 1990, Cancer research.

[8]  C. Nathan,et al.  Reduced biopterin as a cofactor in the generation of nitrogen oxides by murine macrophages. , 1989, The Journal of biological chemistry.

[9]  D. Li,et al.  Chronic progressive multiple sclerosis: Serial magnetic resonance brain imaging over six months , 1989, Annals of neurology.

[10]  D. Li,et al.  Serial magnetic resonance scanning in multiple sclerosis: A second prospective study in relapsing patients , 1989, Annals of neurology.

[11]  M. Marletta,et al.  Macrophage oxidation of L-arginine to nitrite and nitrate: nitric oxide is an intermediate. , 1988, Biochemistry.

[12]  H. Kirchner,et al.  Increased production of interferon gamma and tumor necrosis factor precedes clinical manifestation in multiple sclerosis: Do cytokines trigger off exacerbations? , 1988, Acta neurologica Scandinavica.

[13]  Y. Touitou,et al.  Time-dependence of urinary neopterin, a marker of cellular immune activity. , 1988, Clinical chemistry.

[14]  B E Kendall,et al.  Serial gadolinium enhanced magnetic resonance imaging in multiple sclerosis. , 1988, Brain : a journal of neurology.

[15]  R. Hirsch,et al.  EXACERBATIONS OF MULTIPLE SCLEROSIS IN PATIENTS TREATED WITH GAMMA INTERFERON , 1987, The Lancet.

[16]  A. Alpérovitch,et al.  CLINICAL VIRAL INFECTIONS AND MULTIPLE SCLEROSIS , 1985, The Lancet.

[17]  D. Fuchs,et al.  Immune response-associated production of neopterin. Release from macrophages primarily under control of interferon-gamma , 1984, The Journal of experimental medicine.

[18]  J. Kurtzke.  Rating neurologic impairment in multiple sclerosis , 1983, Neurology.

[19]  H. Powell,et al.  Pathology of multiple sclerosis. , 1983, Neurologic clinics.

[20]  D. Silberberg,et al.  New diagnostic criteria for multiple sclerosis: Guidelines for research protocols , 1983, Annals of neurology.

[21]  W. Staudenmann,et al.  AUTOMATIC HPLC OF PTERINS WITH OR WITHOUT COLUMN SWITCHING , 1982 .

[22]  F. Young.  PTERIDINES , 1955 .

[23]  H. Lassmann,et al.  Histopathology and the blood–cerebrospinal fluid barrier in multiple sclerosis , 1994, Annals of neurology.

[24]  D. Fuchs,et al.  The role of neopterin as a monitor of cellular immune activation in transplantation, inflammatory, infectious, and malignant diseases. , 1992, Critical reviews in clinical laboratory sciences.

[25]  W. L. Benedict,et al.  Multiple Sclerosis , 2007, Journal - Michigan State Medical Society.